CA125 measurements are applied in clinical management of ovarian cancer in different situations including early detection, disease monitoring, early prediction of outcome, tumor status after completion of chemotherapy, and early detection of recurrence (55, 56). This evidence concerns the gene MUC16 and ovarian cancer.